September 14th 2024
Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.
A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.
Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.